Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. director Douglas S. Prince acquired 815 shares of common stock on October 1, 2026, under the non-employee director compensation policy in lieu of quarterly retainer fees. The share count was calculated as $8,117.40 divided by the $9.96 closing price. His reported direct holdings after the transaction were 70,146 shares.
Senseonics Holdings, Inc. director Douglas A. Roeder acquired 1,480 shares of common stock on October 1, 2026, under the company’s non-employee director compensation policy, in lieu of quarterly retainer fees. The shares were valued at $9.96 per share, the closing price that day. Roeder’s directly held position after the transaction was 172,671 shares.
Senseonics Holdings, Inc. director Edward Fiorentino acquired 1,418 shares of common stock on October 1, 2026, through an issuance under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. The share count equaled $14,123.28 divided by the $9.96 closing price on that date. His directly held shares totaled 87,392 after the transaction.
Edelman Steven reported acquisition or exercise transactions in this Form 4 filing. Senseonics Holdings, Inc. director Steven Edelman was issued 1,292 shares of common stock on October 1, 2026, under the company's non-employee director compensation policy in lieu of quarterly retainer fees. The issuance represented $12,868.32 in retainer fees, using $9.96 per share, the closing price that day. His reported direct holdings after the issuance were 92,375 shares.
Senseonics Holdings, Inc. (SENS) director Douglas A. Roeder reported an open-market purchase of 13,953.2843 shares of common stock on 2026-08-19 at a weighted average price of $8.98 per share, in multiple trades between $8.95 and $8.99. Following this transaction, he directly holds 171,191.2843 shares.
Sessa Capital IM, L.P., as investment manager to certain funds, and John Petry report beneficial ownership of Senseonics Holdings, Inc. common stock. They report beneficial ownership of 12,437,532 shares of common stock, including 8,000,000 shares issuable upon exercise of pre-funded warrants held by the Sessa funds. Their reported stake represents 9.9% of the outstanding common stock, based on 52,864,750 shares outstanding as of June 30, 2026. The warrants are subject to a 9.9% “Blocker” that prevents exercises which would cause the reporting persons’ beneficial ownership to exceed 9.9%.
Senseonics Holdings, Inc. reported sharply higher revenue but larger losses for the six months ended June 30, 2026. Total revenue was $26,194 thousand, more than doubling from $12,906 thousand a year earlier, driven mainly by U.S. commercialization of the Eversense E3 and Eversense 365 CGM systems and the transition of European distribution back in-house.
Operating expenses increased substantially as the company built its direct sales, marketing, and support infrastructure and continued product development, resulting in an operating loss of $67,834 thousand and a net loss of $69,038 thousand, or $1.33 basic and diluted net loss per share.
Liquidity improved through equity and debt financing. As of June 30, 2026, the company held $142.7 million in unrestricted cash, cash equivalents and marketable securities. It raised approximately $86.0 million in net proceeds from a May 2026 equity and pre-funded warrant offering, received about $6.2 million via an at-the-market program, and expanded its Hercules senior secured term loan facility to up to $140.0 million, with $55.0 million drawn. Net cash used in operating activities was $62,163 thousand, and management states that available resources and expected cash flows are sufficient for at least the next twelve months.
Senseonics Holdings, Inc. reported record results for the quarter ended June 30, 2026, with total revenue of $14.5 million, an increase of approximately 120% from $6.6 million a year earlier. U.S. revenue rose to $12.6 million, while revenue outside the U.S. was $1.9 million, reflecting the integration of European commercial operations and growth in the Eon Care program.
Gross profit was $8.6 million, for gross margin of approximately 59%, up from 47% in the prior-year quarter. Higher investment in the Gemini and Freedom development programs and commercial integration drove research and development expenses to $11.6 million and selling, general and administrative expenses to $32.9 million, resulting in a net loss of $36.7 million, or $0.63 per share. As of June 30, 2026, cash, restricted cash and cash equivalents totaled $143.0 million and outstanding indebtedness was $55.5 million. Senseonics raised its full-year 2026 revenue guidance to $62–$66 million and gross margin guidance to 58%–61%, citing commercial momentum and the global roll-out of Eversense 365.
BlackRock, Inc. has reported a passive ownership stake in SENSEONICS HOLDINGS, INC. common stock on Schedule 13G. As of June 30, 2026, BlackRock and certain of its business units beneficially owned 2,764,170 shares of SENSEONICS common stock, representing 6.6% of the outstanding class. BlackRock reports sole voting powersole dispositive power
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received a grant of 1,515 shares of common stock. This stock was issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees. The grant value equaled $8,120.40, based on a $5.36 closing share price. Following this award, Prince directly holds 69,331 shares of Senseonics common stock.